Anticoagulant Reversal Drugs Market
Anticoagulant Reversal Drugs Market Forecast by Product (Prothrombin Complex Concentrates, Vitamin K, Protamine, Tranexamic Acid, Idarucizumab, Andexxa), by Distribution Channel (Hospital, Retail Pharmacies), & by Region - Global Insights 2023 to 2033
Analysis of Anticoagulant Reversal Drugs market covering 30 + countries including analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more
Anticoagulant Reversal Drugs Market outlook (2022-2032)
In FY 2022, the Anticoagulant Reversal Drugs market reached a valuation of US$ 989.0 Million and is likely to register a Y-o-Y growth rate of 13.0% in 2023, closing at US$ 1,137.35 Million. Furthermore, across the 2022-2032 period of assessment, growth is expected to accelerate at a whopping 15.0% CAGR, reaching US$ 4,601.22 Million.
Report Attributes |
Details |
|---|---|
|
Anticipated Base Year Value (2022) |
US$ 989.0 Million |
|
Expected Market Value (2023) |
US$ 1,137.35 Million |
|
Projected Forecast Value (2033) |
US$ 4,601.22 Million |
|
Global Growth Rate (2022-2032) |
15.0% CAGR |
|
Expected Growth Rate of the North American Market (2022-2032) |
14.8% CAGR |
|
Anticipated Growth Rate of the Asia Pacific Market (2022-2032) |
14.7% CAGR |
|
Prominent Service Players |
|
Bleeding disorders can happen as a result of some medications, such as blood thinner, which includes warfarin, heparin, and aspirin. The high risk of bleeding varies with the anticoagulant agent used. According to the National Center for Biotechnology Information (NCBI) data, the occurrence of bleeding for patients taking warfarin has been projected at 15-20% each year.
Life-threatening bleeding because of warfarin has been projected at a rate of 1-3% per year. Thus, the increase in demand for anticoagulant therapies is further creating potential opportunities for reversal agents for anticoagulants.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
2017-2021 Revenue Analysis of Anticoagulant Reversal Drugs Market vs. Growth Outlook 2022-2032
According to Fact.MR, market research and competitive intelligence provider, the global market for anticoagulant reversal drugs expanded at a 7.7% CAGR from 2017 to 2022, topping US$ 860.0 Million as of 2021.
Increasing demand for anticoagulant reversal drugs in case of uncontrolled bleeding is expected to drive the market growth during the forecast period. Some of the common bleeding disorders include blood clots, Von Willebrand disease, and hemophilia A and B.
Moreover, rise in usage of reversal agents for life-threatening conditions or uncontrolled bleeding is projected to drive the global market size in the near future. Increase in cases of bleeding is anticipated to lead to unmet clinical needs owing to the unavailability of specific reversal agents.
Key Market Drivers Influencing Anticoagulant Reversal Drugs Industry Expansion
Increase in Bleeding Disorders among People to Foster Market Growth Prospects
Several bleeding disorders include blood clots, hemophilia A and B, and Von Willebrand disease (VWD). As per the data by the National Hemophilia Foundation (NHF), approximately 30,000 to 33,000 people are surviving in the U.S. with hemophilia and 60% of them suffer from severe hemophilia.
The CDC reports that around 400 babies are annually born with hemophilia A. This disease called Von Willebrand disease is one of the most common bleeding disorders affecting 1 in every 100 people.
There are tremendous complications of bleeding disorders that affect blood clotting and might result in extreme bleeding inside and outside the patient’s body. This enables the need for anticoagulants, which gives rise to the demand for anticoagulant reversal drugs during uncontrolled bleeding.
Rise in the Population of Elderly People to Fuel the Market Growth
According to the World Health Organization (WHO), people over the age of 65 are the fastest demographic segment in the world. Between 2000 and 2050, the proportion of the world's population over the age of 60 is expected to double, increasing from about 11% to 22%.
As per the reports of the CDC, approximately 2% of people below 65 years of age have atrial fibrillation, while 9% of people who are above 65 years of age have the disease. It is also estimated that almost 12.1 million people will develop atrial fibrillation by 2030. As a result, the growing elderly population is driving the global market growth during the forecast period.
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
Key Challenges encountered by Anticoagulant Reversal Drugs Industry
High Expenditure Cost of Coagulant Reversal Drugs to Hamper the Market Growth
The huge expenditure on anticoagulant reversal drugs is one of the major factors that is anticipated to hinder the growth of the market over the analysis period.
As per the American College of Cardiology, 4-F PCC (Kcentra) helps in treating bleeding cases caused by rivaroxaban and apixaban and it is dosed at 50 units/kg. Its average wholesale price is USD 2.90 per unit, therefore treating a patient whose weight is 100 kg would cost around USD 14,500.
Side Effects of Medicines to Affect the Market Growth
Some types of medicines can adversely affect the health of the population, especially the elderly. Sometimes, it may result in excessive bleeding and the higher dosage can lead to many complications. Therefore, the side effects of drugs limit the expansion of the global market.
Region-wise Analysis
How will North America Perform in the Global Anticoagulant Reversal Drugs Industry Landscape?
Increase in Prevalence of Cardiovascular Diseases to Boost the Market Growth
North America held the largest revenue share of 41.1% in 2021 and is expected to maintain the lead throughout the forecast period. The U.S. accounted for the leading share in the North American market. Key factors contributing to its growth include high healthcare expenditure and favorable healthcare reimbursement policies for costly drugs. In addition, the easy availability of these reversal drugs during emergency conditions and growing cases of surgery and higher approvals of drugs are some factors that are driving the regional market.
In the region, the United States holds the largest market share due to the accelerated drug approval initiative by the USFDA, and the initiation of various prevention programs and awareness workshops for blood disorders by the Centers for Disease Control and Prevention, which is expected to drive the market growth in this region.
Furthermore, the high prevalence of cardiovascular diseases in the United States drives the studied market. According to the American Heart Association, every 40 seconds, an American will have a myocardial infarction, and coronary events are estimated to occur in about 1,055,000 individuals, including 720,000 new and 335,000 recurrent coronary events in 2019 in the United States. According to Fact.MR, North America is expected to expand at a CAGR of 14.8% until 2032.
How will the Growth of Anticoagulant Reversal Drugs Market Escalate across Asia Pacific?
Increasing Geriatric Population to Enhance the Market Prospects
The market in Asia Pacific is projected to grow at a rapid pace during the forecast period. Increase in geriatric population in Japan and China, high prevalence & rise in incidence rates of arterial fibrillation, and new product commercialization are anticipated to propel the market in Asia Pacific during the forecast period.
In addition, increasing awareness and rising incidence of bleeding disorders are propelling the demand for anticoagulant reversal drugs in this region. Asia-Pacific leads the market due to the developing healthcare facilities, large number of generic manufacturer and rise in government initiatives and specialist communities.
Other key factors contributing to the market growth in the region include high healthcare expenditure and favorable healthcare reimbursement policies for costly drugs. In addition, the easy availability of these reversal drugs during emergency conditions is driving the regional market. According to Fact.MR, Asia Pacific is expected to expand at a CAGR of 14.7% until 2032.
Region-wise Forecast CAGRs for the Anticoagulant Reversal Drugs Market
| Region | CAGR |
|
North America |
14.8% |
|
Asia Pacific |
14.7% |
|
Europe |
14.6% |
|
Middle East & Africa |
14.5% |
|
Latin America |
14.4% |
Category-wise Insights
Which is the Most Sought-after Product Category?
Increased Usage of Idarucizumab Drug to Boost the Segment’s Growth
In terms of product, Idarucizumab segment is prospective to earn greater traction, expanding at a CAGR of 14.3% over the forecast period. Idarucizumab market segment for anticoagulant reversal drugs accounted for the largest revenue share in 2020, and likely to witness the highest growth rate over the analysis period.
This high share is attributed to its high potential and legacy drug being effective. Moreover, the drug is in more demand due to its high efficacy and specificity. However, the Andexanet alfa segment is projected to witness the highest growth rate over the assessment period. The expected growth is due to the approval of the anticoagulant reversal drug in key geographic markets.
For instance, in 2020, the Centers for Medicare & Medicaid Services (CMS) allocated a permanent reimbursement code J for the concerned drug Andexxa, facilitating an easy reimbursement system for the drug in the outpatient settings. Hence, a favorable reimbursement scenario for the drug in the major developed markets is projected to support the segment’s market growth prospects in anticoagulant reversal drugs industry.
Which Segment to Remain Dominant in the Distribution Channel Category?
Hospital Pharmacy Segment to Enhance Growth Prospects
Based on distribution channel, hospital pharmacy segment dominated the market with a 52.2% share in 2021. This is attributed to the fact that hospitals are the primary centers for the diagnosis and treatment of different types of bleeding disorders. Uncontrolled bleeding during emergency conditions is further driving the segment. In terms of distribution channel, the segment is prospective to earn greater traction, expanding at a CAGR of 14.5% over the forecast period.
Anticoagulant Reversal Drugs Market- Competitive Landscape
Prominent players in the Anticoagulant Reversal Drugs Industry are taking advantage of the rapidly increasing demand in various applications. To further their outreach, players are relying on collaborations, partnerships and acquisitions with existing small, medium and large-scale vendors. Some prominent market developments are as follows:
- In October 2021, Alveron Pharma BV raised EUR 3.9 Mn to fund the continued development of OKL-1111, a first in class drug to treat anticoagulant-related bleeding.
- In July 2020, VarmX, a renowned biotech company, raised EUR 32 Mn in series B financing to develop an innovative reversal agent for the treatment and prevention of severe bleeding in patients on oral anticoagulants.
- In July 2020, Janssen Research and Development LLC began the Phase 1 clinical trial for the evaluation of the reversal of the anticoagulation effect of the drug JNJ-70033093 by 4-Factor Prothrombin Complex Concentrate (4F-PCC) and Recombinant Human Factor VIIa.
- In July 2020, Portola Pharmaceuticals Inc. announced the establishment of a permanent J-code (J7169) by the Centers for Medicare & Medicaid Services (CMS) for Andexxa, a recombinant coagulation factor Xa, which allows reimbursement in the hospital outpatient settings.
Key Segments Covered in the Anticoagulant Reversal Drugs Industry Survey
-
By Product :
- Prothrombin Complex Concentrates
- Vitamin K
- Protamine
- Tranexamic Acid
- Idarucizumab
- Andexxa
- Others
-
By Distribution Channel :
- Hospital Pharmacies
- Retail Pharmacies
- Others
-
By Region :
- North America
- Europe
- Latin America
- Asia Pacific
- Middle East & Africa
Table of Content
1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 2. Assumptions and Acronyms Used 3. Research Methodology 4. Executive Summary 5. Market Overview 5.1. Product Overview 5.2. Market Dynamics 5.2.1. Drivers 5.2.1.1. Rise in the prevalence of atrial fibrillation in aging population 5.2.1.2. Increase in the prevalence of ICH and GI hemorrhages 5.2.1.3. NTAP status for specific drugs 5.2.2. Restraints 5.2.2.1. Challenges associated with the development of anticoagulant reversal drugs 5.2.2.2. Risk associated with reversing anticoagulation 5.2.3. Opportunities 5.2.3.1. Unmet clinical needs 5.2.3.2. Untapped market in emerging economies 5.2.4. Global Anticoagulant Reversal Drugs Market Value (US$ Mn) Forecast, 2023-2033 5.2.5. Global Anticoagulant Reversal Drugs Market Outlook 5.2.6. Key Industry Developments 5.2.7. Regulatory Scenario 5.2.8. Reimbursement Scenario 5.2.9. Pipeline Analysis 5.2.10. Healthcare Overview 6. Global Anticoagulant Reversal Drugs Market Analysis, by Product 6.1. Introduction 6.2. Global Anticoagulant Reversal Drugs Market Value Share Analysis, by Product 6.3. Global Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2023-2033 6.3.1. Prothrombin Complex Concentrates (PCC) 6.3.2. Vitamin K 6.3.3. Protamine 6.3.4. Tranexmic Acid 6.3.5. Idarucizumab 6.3.6. Andexxa 6.3.7. Others 6.4. Market Attractiveness, by Product 7. Global Anticoagulant Reversal Drugs Market Analysis, by Distribution Channel 7.1. Introduction 7.2. Global Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel 7.3. Global Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2022-2032 7.3.1. Hospital Pharmacies 7.3.2. Retail Pharmacies 7.3.3. Others 7.4. Market Attractiveness, by Distribution Channel 8. Global Anticoagulant Reversal Drugs Market Analysis, by Region 8.1. Introduction 8.2. Global Anticoagulant Reversal Drugs Market Value Share Analysis, by Region 8.2.1. North America 8.2.2. Europe 8.2.3. Asia Pacific 8.2.4. Latin America 8.2.5. Middle East & Africa 8.3. Market Attractiveness Analysis, by Region 9. North America Anticoagulant Reversal Drugs Market Analysis 9.1. Key Findings 9.2. North America Anticoagulant Reversal Drugs Market Value Forecast, by Country, 2023-2033 9.2.1. U.S. 9.2.2. Canada 9.3. North America Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2022-2032 9.3.1. Prothrombin Complex Concentrates (PCC) 9.3.2. Vitamin K 9.3.3. Protamine 9.3.4. Tranexmic Acid 9.3.5. Idarucizumab 9.3.6. Andexxa 9.3.7. Others 9.4. North America Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2022-2032 9.4.1. Hospital Pharmacies 9.4.2. Retail Pharmacies 9.4.3. Others 9.5. North America Market Attractiveness Analysis 9.5.1. By Country 9.5.2. By Product 9.5.3. By Distribution Channel 10. Europe Anticoagulant Reversal Drugs Market Analysis 10.1. Key Findings 10.2. Europe Anticoagulant Reversal Drugs Market Value Forecast, by Country/Sub-region, 2023-2033 10.2.1. U.K. 10.2.2. Germany 10.2.3. France 10.2.4. Italy 10.2.5. Spain 10.2.6. Rest of Europe 10.3. Europe Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2022-2032 10.3.1. Prothrombin Complex Concentrates (PCC) 10.3.2. Vitamin K 10.3.3. Protamine 10.3.4. Tranexmic Acid 10.3.5. Idarucizumab 10.3.6. Andexxa 10.3.7. Others 10.4. Europe Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2022-2032 10.4.1. Hospital Pharmacies 10.4.2. Retail Pharmacies 10.4.3. Others 10.5. Europe Market Attractiveness Analysis 10.5.1. By Country/Sub-region 10.5.2. By Product 10.5.3. By Distribution Channel 11. Asia Pacific Anticoagulant Reversal Drugs Market Analysis 11.1. Key Findings 11.2. Asia Pacific Anticoagulant Reversal Drugs Market Value Forecast, by Country/Sub-region, 2023-2033 11.2.1. China 11.2.2. Japan 11.2.3. India 11.2.4. Australia 11.2.5. Rest of Asia Pacific 11.3. Asia Pacific Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2022-2032 11.3.1. Prothrombin Complex Concentrates (PCC) 11.3.2. Vitamin K 11.3.3. Protamine 11.3.4. Tranexmic Acid 11.3.5. Idarucizumab 11.3.6. Andexxa 11.3.7. Others 11.4. Asia Pacific Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2022-2032 11.4.1. Hospital Pharmacies 11.4.2. Retail Pharmacies 11.4.3. Others 11.5. Asia Pacific Market Attractiveness Analysis 11.5.1. By Country/Sub-region 11.5.2. By Product 11.5.3. By Distribution Channel 12. Latin America Anticoagulant Reversal Drugs Market Analysis 12.1. Key Findings 12.2. Latin America Anticoagulant Reversal Drugs Market Value Forecast, by Country/Sub-region, 2023-2033 12.2.1. Brazil 12.2.2. Mexico 12.2.3. Rest of Latin America 12.3. Latin America Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2022-2032 12.3.1. Prothrombin Complex Concentrates (PCC) 12.3.2. Vitamin K 12.3.3. Protamine 12.3.4. Tranexmic Acid 12.3.5. Idarucizumab 12.3.6. Andexxa 12.3.7. Others 12.4. Latin America Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2022-2032 12.4.1. Hospital Pharmacies 12.4.2. Retail Pharmacies 12.4.3. Others 12.5. Latin America Market Attractiveness Analysis 12.5.1. By Country/Sub-region 12.5.2. By Product 12.5.3. By Distribution Channel 13. Middle East & Africa Anticoagulant Reversal Drugs Market Analysis 13.1. Key Findings 13.2. Middle East & Africa Anticoagulant Reversal Drugs Market Value Forecast, by Country/Sub-region, 2023-2033 13.2.1. GCC Countries 13.2.2. South Africa 13.2.3. Israel 13.2.4. Rest of Middle East & Africa 13.3. Middle East & Africa Anticoagulant Reversal Drugs Market Value Forecast, by Product, 2022-2032 13.3.1. Prothrombin Complex Concentrates (PCC) 13.3.2. Vitamin K 13.3.3. Protamine 13.3.4. Tranexmic Acid 13.3.5. Idarucizumab 13.3.6. Andexxa 13.3.7. Others 13.4. Middle East & Africa Anticoagulant Reversal Drugs Market Value Forecast, by Distribution Channel, 2022-2032 13.4.1. Hospital Pharmacies 13.4.2. Retail Pharmacies 13.4.3. Others 13.5. Middle East & Africa Market Attractiveness Analysis 13.5.1. By Country/Sub-region 13.5.2. By Product 13.5.3. By Distribution Channel 14. Competitive Landscape 14.1. Competition Matrix 14.2. Anticoagulant Reversal Drugs Market Share Analysis, by Company (2023) 14.3. Company Profiles 14.3.1. Bausch Health Companies, Inc. 14.3.1.1. Company Overview (Headquarters, Business Segments, Employee Strength) 14.3.1.2. Financial Overview 14.3.1.3. Product Portfolio 14.3.1.4. SWOT Analysis 14.3.1.5. Strategic Overview 14.3.2. Pfizer, Inc. 14.3.2.1. Company Overview (Headquarters, Business Segments, Employee Strength) 14.3.2.2. Financial Overview 14.3.2.3. Product Portfolio 14.3.2.4. SWOT Analysis 14.3.2.5. Strategic Overview 14.3.3. Fresenius Kabi AG 14.3.3.1. Company Overview (Headquarters, Business Segments, Employee Strength) 14.3.3.2. Financial Overview 14.3.3.3. Product Portfolio 14.3.3.4. SWOT Analysis 14.3.3.5. Strategic Overview 14.3.4. Amneal Pharmaceuticals, Inc. 14.3.4.1. Company Overview (Headquarters, Business Segments, Employee Strength) 14.3.4.2. Financial Overview 14.3.4.3. Product Portfolio 14.3.4.4. SWOT Analysis 14.3.4.5. Strategic Overview 14.3.5. Boehringer Ingelheim GmbH 14.3.5.1. Company Overview (Headquarters, Business Segments, Employee Strength) 14.3.5.2. Financial Overview 14.3.5.3. Product Portfolio 14.3.5.4. SWOT Analysis 14.3.5.5. Strategic Overview 14.3.6. CSL Limited 14.3.6.1. Company Overview (Headquarters, Business Segments, Employee Strength) 14.3.6.2. Financial Overview 14.3.6.3. Product Portfolio 14.3.6.4. SWOT Analysis 14.3.6.5. Strategic Overview 14.3.7. Octapharma AG 14.3.7.1. Company Overview (Headquarters, Business Segments, Employee Strength) 14.3.7.2. Financial Overview 14.3.7.3. Product Portfolio 14.3.7.4. SWOT Analysis 14.3.7.5. Strategic Overview 14.3.8. Portola Pharmaceuticals, Inc. 14.3.8.1. Company Overview (Headquarters, Business Segments, Employee Strength) 14.3.8.2. Financial Overview 14.3.8.3. Product Portfolio 14.3.8.4. SWOT Analysis 14.3.8.5. Strategic Overview 14.3.9. Perosphere Pharmaceuticals, Inc. (acquired by AMAG Pharmaceuticals, Inc.) 14.3.9.1. Company Overview (Headquarters, Business Segments, Employee Strength) 14.3.9.2. Financial Overview 14.3.9.3. Product Portfolio 14.3.9.4. SWOT Analysis 14.3.9.5. Strategic Overview
Don't Need a Global Report?
save 40%! on Country & Region specific reports
List Of Table
Table 01: Reimbursement Scenario for AndeXXa
Table 02: Reimbursement Scenario for Praxbind
Table 03: Reimbursement Scenario for Kcentra
Table 04: Pipeline Analysis
Table 05: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2022-2032
Table 06: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2022-2032
Table 07: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Region, 2022-2032
Table 08: North America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Country, 2022-2032
Table 09: North America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2022-2032
Table 10: North America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2022-2032
Table 11: Europe Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2022-2032
Table 12: Europe Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2022-2032
Table 13: Europe Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2022-2032
Table 14: Asia Pacific Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2022-2032
Table 15: Asia Pacific Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2022-2032
Table 16: Asia Pacific Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2022-2032
Table 17: Latin America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2022-2032
Table 18: Latin America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2022-2032
Table 19: Latin America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2022-2032
Table 20: Middle East & Africa Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Country/Sub-region, 2022-2032
Table 21: Middle East & Africa Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Product, 2022-2032
Table 22: Middle East & Africa Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2022-2032
More Insights, Lesser Cost (-50% off)
Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR
List Of Figures
Figure 01: Anticoagulant Reversal Drugs Market Size (US$ Mn) and Distribution, by Region, 2023 and 2033
Figure 02: Global Anticoagulant Reversal Drugs Market Size (US$ Mn) and Forecast, 2022-2032
Figure 03: Market Value Share, by Product (2023)
Figure 04: Market Value Share, by Distribution Channel (2023)
Figure 05: Market Value Share, by Region (2023)
Figure 06: Regulatory Approval Process - U.S.
Figure 07: Regulatory Approval Process - Europe
Figure 08: Regulatory Approval Process - Japan
Figure 09: Global Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2023 and 2033
Figure 10: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Prothrombin Complex Concentrates (PCC) 2022-2032
Figure 11: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Vitamin K, 2022-2032
Figure 12: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Protamine, 2022-2032
Figure 13: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Tranexamic Acid, 2022-2032
Figure 14: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Others, 2022-2032
Figure 15: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Idarucizumab, 2022-2032
Figure 16: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by AndeXXa, 2022-2032
Figure 17: Global Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2022-2032
Figure 18: Global Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2033
Figure 19: Global Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2032
Figure 20: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Hospital Pharmacies, 2022-2032
Figure 21: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Retail Pharmacies, 2022-2032
Figure 22: Global Anticoagulant Reversal Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Others, 2022-2032
Figure 23: Global Anticoagulant Reversal Drugs Market Value Share, by Region, 2023 and 2033
Figure 24: Global Anticoagulant Reversal Drugs Market Attractiveness, by Region, 2022-2032
Figure 25: North America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2032
Figure 26: North America Anticoagulant Reversal Drugs Market Value Share Analysis, by Country, 2023 and 2033
Figure 27: North America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Country, 2023-2033
Figure 28: North America Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2023 and 2033
Figure 29: North America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2022-2032
Figure 30: North America Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2033
Figure 31: North America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2032
Figure 32: Europe Anticoagulant Reversal Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2032
Figure 33: Europe Anticoagulant Reversal Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2033
Figure 34: Europe Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2023-2033
Figure 35: Europe Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2023 and 2033
Figure 36: Europe Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2022-2032
Figure 37: Europe Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2033
Figure 38: Europe Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2032
Figure 39: Asia Pacific Anticoagulant Reversal Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2032
Figure 40: Asia Pacific Anticoagulant Reversal Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2033
Figure 41: Asia Pacific Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022-2032
Figure 42: Asia Pacific Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2023 and 2033
Figure 43: Asia Pacific Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2022-2032
Figure 44: Asia Pacific Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2033
Figure 45: Asia Pacific Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2032
Figure 46: Latin America Anticoagulant Reversal Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2032
Figure 47: Latin America Anticoagulant Reversal Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2033
Figure 48: Latin America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022-2032
Figure 49: Latin America Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2023 and 2033
Figure 50: Latin America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2022-2032
Figure 51: Latin America Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2033
Figure 52: Latin America Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2032
Figure 53: Middle East & Africa Anticoagulant Reversal Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, 2022-2032
Figure 54: Middle East & Africa Anticoagulant Reversal Drugs Market Value Share Analysis, by Country/Sub-region, 2023 and 2033
Figure 55: Middle East & Africa Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2022-2032
Figure 56: Middle East & Africa Anticoagulant Reversal Drugs Market Value Share Analysis, by Product, 2023 and 2033
Figure 57: Middle East & Africa Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Product, 2022-2032
Figure 58: Middle East & Africa Anticoagulant Reversal Drugs Market Value Share Analysis, by Distribution Channel, 2023 and 2033
Figure 59: Middle East & Africa Anticoagulant Reversal Drugs Market Attractiveness Analysis, by Distribution Channel, 2022-2032
Figure 60: Global Anticoagulant Reversal Drugs Market Share Analysis, by Company (2023)
Figure 61: Product Overview - Bausch Health Companies, Inc.
Figure 62: Breakdown of Net Sales (%), by Region, 2023 - Bausch Health Companies, Inc.
Figure 63: Revenue (US$ Mn), 2017–2022 - Bausch Health Companies, Inc.
Figure 64: R&D Expenses (US$ Mn), 2023-2033 - Bausch Health Companies, Inc.
Figure 65: Product Overview - Pfizer, Inc.
Figure 66: Breakdown of Net Sales, by Region, 2023 - Pfizer, Inc.
Figure 67: Revenue (US$ Bn) and Y-o-Y Growth (%), 2017–2022 - Pfizer, Inc.
Figure 68: R&D Intensity and Sales & Marketing Intensity - Company Level, 2022-2032 - Pfizer, Inc.
Figure 69: Product Overview - Fresenius Kabi AG
Figure 70: Revenue (US$ Mn) & Y-o-Y Growth (%), 2022-2032 - Fresenius Kabi AG
Figure 71: Breakdown of Net Sales, by Region, 2017 - Fresenius Kabi AG
Figure 72: Breakdown of Net Sales, by Segment, 2017 - Fresenius Kabi AG
Figure 73: Research & Development Cost, 2023 - 2033 (US$ Mn) - Fresenius Kabi AG
Figure 74: Product Overview - Amneal Pharmaceuticals, Inc.
Figure 75: Product Overview - Boehringer Ingelheim GmbH
Figure 76: Revenue (US$ Bn) and Y-o-Y Growth (%), 2022-2032 - Boehringer Ingelheim GmbH
Figure 77: Breakdown of Net Sales, by Business and Business Segment Level, 2023 - Boehringer Ingelheim GmbH
Figure 78: Breakdown of Net Sales, by Region (Company Level), 2023 - Boehringer Ingelheim GmbH
Figure 79: R&D Expenditure (US$ Bn), 2017–2022 - Boehringer Ingelheim GmbH
Figure 80: Product Overview: CSL Limited
Figure 81: Total Revenue (US$ Mn) and Y-o-Y Growth, 2022-2032 – CSL Limited
Figure 82: R&D Investment, (US$ Mn) and Y-o-Y Growth, 2022-2032 - CSL Limited
Figure 83: Sales Revenue (US$ Mn) and Y-o-Y Growth, 2022-2032 - CSL Limited
Figure 84: Net Profit (US$ Mn), 2022-2032 - CSL Limited
Figure 85: Product Overview - Octapharma AG
Figure 86: Revenue (US$ Mn) and Y-o-Y Growth, 2017–2022 - Octapharma AG
Figure 87: R&D and Selling and Marketing Expenses, (US$ Mn), 2022-2032 - Octapharma AG
Figure 88: Year-end Employee Headcount and Y-o-Y Growth, 2023-2033 - Octapharma AG
Figure 89: Gross profit (US$ Mn) and Y-o-Y Growth, 2022-2032 - Octapharma AG
Figure 90: Product Overview - Portola Pharmaceuticals, Inc.
Figure 91: R&D and Selling and Marketing Expenses, (US$ Mn), 2022-2032 - Portola Pharmaceuticals, Inc.
Figure 92: Revenue (US$ Mn) and Y-o-Y Growth, 2017–2022 - Portola Pharmaceuticals, Inc.
Figure 93: Product Overview - Perosphere Pharmaceuticals Inc.
Know thy Competitors
Competitive landscape highlights only certain players
Complete list available upon request
- FAQs -
What is the expected closing market value for anticoagulant reversal drugs in 2032?
The anticoagulant reversal drugs landscape is slated to reach a valuation of US$ 4,601.22 Million by 2033.
How will the North American market for Anticoagulant Reversal Drugs flourish until 2032?
As per Fact.MR’s projections, the market for anticoagulant reversal drugs in North America will likely expand at a 14.8% CAGR.
At what percentage will the industry expand during the 2022-2032 period of assessment?
From 2022 to 2032, the Anticoagulant Reversal Drugs industry is poised to flourish at a 15.0% CAGR.
At what value will the Anticoagulant Reversal Drugs market close in 2022?
Fact.MR expects the Anticoagulant Reversal Drugs industry to be valued at US$ 1,137.35 Million as of 2022.
By product, which segment is likely to experience the fastest growth rate?
Idarucizumab Segment is expected to grow the fastest, at a CAGR of 14.3%.
Which is the most preferred distribution channel category of anticoagulant reversal drugs?
By distribution channel, the hospital pharmacy segment is expected to dominate the market, documenting a 14.5% value CAGR.
What will be the growth scenario for the market in Asia Pacific until 2033?
Asia Pacific is poised to yield a CAGR of 14.7% with respect to anticoagulant reversal drugs in 2032.
What was the market worth for anticoagulant reversal drugs in 2021?
As of 2021, the Anticoagulant Reversal Drugs market was valued at US$ 989.0 Million.
What was the documented growth rate for the anticoagulant reversal drugs market from 2017-2021?
According to Fact.MR, a CAGR of 7.7% was recorded for the anticoagulant reversal drugs market from 2017-2021.
Anticoagulant Reversal Drugs Market